The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population‐based study in the Netherlands

Lina van der Straten(Erasmus MC), Avinash G. Dinmohamed(Netherlands Comprehensive Cancer Organisation), Otto Visser(Netherlands Comprehensive Cancer Organisation), Arnon P. Kater(Amsterdam University Medical Centers), Jan J. Cornelissen(Erasmus MC), Mark‐David Levin(Albert Schweitzer Hospital), Nicole M. A. Blijlevens(Radboud University Nijmegen), Jeanette K. Doorduijn(Erasmus MC Cancer Institute)
British Journal of Haematology
January 28, 2020
10.1111/bjh.16391
Cited by 7

Related Papers

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis
|Journal of Clinical Oncology|2010|478
Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation
|Blood|2002|401